|
Neurologic Examination
|
D009460 |
[Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system.
] |
|
Neurologic Manifestations
|
D009461 |
[Clinical signs and symptoms caused by nervous system injury or dysfunction.
] |
|
Neurological Rehabilitation
|
D000066530 |
[Physician-supervised programs designed to rehabilitate people with diseases, trauma, or disorders of the NERVOUS SYSTEM.
] |
|
Neurologists
|
D000072141 |
[Qualified medical professionals who specialize in treating NERVOUS SYSTEM DISEASES.
] |
|
Neurology
|
D009462 |
[A medical specialty concerned with the study of the structures, functions, and diseases of the nervous system.
] |
|
Neurolymphomatosis
|
D000077162 |
[Infiltration of the nervous system by malignant lymphoma cells.
] |
|
Neuroma
|
D009463 |
[A tumor made up of nerve cells and nerve fibers. (Dorland, 27th ed)
] |
|
Neuroma, Acoustic
|
D009464 |
[A benign SCHWANNOMA of the eighth cranial nerve (VESTIBULOCOCHLEAR NERVE), mostly arising from the vestibular branch (VESTIBULAR NERVE) during the fifth or sixth decade of life. Clinical manifestations include HEARING LOSS; HEADACHE; VERTIGO; TINNITUS; and FACIAL PAIN. Bilateral acoustic neuromas are associated with NEUROFIBROMATOSIS 2. (From Adams et al., Principles of Neurology, 6th ed, p673)
] |
|
Neuromuscular Agents
|
D009465 |
[Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
] |
|
Neuromuscular Blockade
|
D019148 |
[The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.
] |
|
Neuromuscular Blocking Agents
|
D009466 |
[Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). Both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.
] |
|
Neuromuscular Depolarizing Agents
|
D009467 |
[Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation.
] |
|
Neuromuscular Diseases
|
D009468 |
[A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.
] |
|
Neuromuscular Junction
|
D009469 |
[The synapse between a neuron and a muscle.
] |
|
Neuromuscular Junction Diseases
|
D020511 |
[Conditions characterized by impaired transmission of impulses at the NEUROMUSCULAR JUNCTION. This may result from disorders that affect receptor function, pre- or postsynaptic membrane function, or ACETYLCHOLINESTERASE activity. The majority of diseases in this category are associated with autoimmune, toxic, or inherited conditions.
] |
|
Neuromuscular Manifestations
|
D020879 |
[Signs and symptoms associated with diseases of the muscle, neuromuscular junction, or peripheral nerves.
] |
|
Neuromuscular Monitoring
|
D061886 |
[The use of peripheral nerve stimulation to assess transmission at the NEUROMUSCULAR JUNCTION, especially in the response to anesthetics, such as the intensity of NEUROMUSCULAR BLOCKADE by NEUROMUSCULAR BLOCKING AGENTS.
, Measuring the response of a muscle to four consecutive stimuli delivered along the path of the muscle's innervating nerve to test the level of NEUROMUSCULAR BLOCKADE.
] |
|
Neuromuscular Nondepolarizing Agents
|
D003473 |
[Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants.
] |
|
Neuromyelitis Optica
|
D009471 |
[A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.
] |
|
Neuronal Apoptosis-Inhibitory Protein
|
D051616 |
[An inhibitor of apoptosis protein that was initially identified during analysis of CHROMOSOME DELETIONS associated with SPINAL MUSCULAR ATROPHY. Naip contains a nucleotide binding oligomerization domain and a carboxy-terminal LEUCINE rich repeat.
] |
